The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.
A significant percentage of newly diagnosed cancer patients will develop brain metastases. For many of these patients, stereotactic radiosurgery (SRS) is recommended as a primary treatment option. Concerns about complexity, patient safety, cost, and human resources can make SRS challenging. HyperArc radiotherapy addresses these challenges by introducing key technology and workflow elements to streamline multi-leaf collimator-based, non-coplanar SRS. HyperArc is designed to deliver SRS treatments from the TrueBeam linear accelerator platform. The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.
Study Type
OBSERVATIONAL
Enrollment
968
HyperArc is a radiotherapy treatment with a structured workflow to plan and deliver stereotactic radiosurgery (SRS).
University of Alabama
Birmingham, Alabama, United States
Icon Cancer Centre Canberra
Bruce, Australian Capital Territory, Australia
Icon Cancer Centre Greenslopes
Greenslopes, Queensland, Australia
Icon Cancer Centre Maroochydore
Maroochydore, Queensland, Australia
Survival
Survival
Time frame: follow until death, on average approximately 2 years
Local tumor control
Response of treated tumors
Time frame: follow until death, on average approximately 2 years
HyperArc Patterns of Care
Dosimetry information for clinically delivered HyperArc treatments
Time frame: Limited to course of treatment: up to 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Icon Cancer Centre Gold Coast Private
Southport, Queensland, Australia
University Hospital Leuven
Leuven, Belgium
L'IRCCS Ospedale Sacro Cuore - Don Calabria
Negrar, Valpolicella, Italy